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Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Both ‘‘uncomplicated’’ and ‘‘compli-
cated’’ forms have been described with various modes of inheritance. Sixteen loci for autosomal-recessive ‘‘complicated’’ HSP have been
mapped. The SPG15 locus was ﬁrst reported to account for a rare form of spastic paraplegia variably associated with mental impairment,
pigmentedmaculopathy, dysarthria, cerebellar signs, and distal amyotrophy, sometimes designated as Kjellin syndrome. Here, we report
the reﬁnement of SPG15 to a 2.64Mb genetic interval on chromosome 14q23.3-q24.2 and the identiﬁcation of ZFYVE26, which encodes
a zinc-ﬁnger protein with a FYVE domain that we named spastizin, as the cause of SPG15. Six different truncatingmutations were found
to segregate with the disease in eight families with a phenotype that included variable clinical features of Kjellin syndrome. ZFYVE26
mRNA was widely distributed in human tissues, as well as in rat embryos, suggesting a possible role of this gene during embryonic de-
velopment. In the adult rodent brain, its expression proﬁle closely resembled that of SPG11, another gene responsible for complicated
HSP. In cultured cells, spastizin colocalized partially with markers of endoplasmic reticulum and endosomes, suggesting a role in
intracellular trafﬁcking.Introduction
The hereditary spastic paraplegias (HSPs) are inherited neu-
rological disorders characterized by progressive lower-limb
spasticity,1,2 with an estimated prevalence of 1.27–9.6/
100,000.3,4 The disease is characterized pathologically by
axonal degeneration in the long ascending and descend-
ing tracts of the spinal cord, especially in their terminal
portions, associated with syndrome-speciﬁc degeneration
of other structures.5 Although the corticospinal tracts are
predominantly affected, the columns of Goll and the spi-
nocerebellar tracts are also involved.
HSP is classiﬁed according to (1) the absence (‘‘uncom-
plicated’’ or ‘‘pure’’ HSP) or presence (‘‘complicated’’ or
‘‘complex’’ HSP) of additional neurological symptoms,
including mental retardation, dementia, behavioral distur-
bances, deafness, cerebellar ataxia, distal amyotrophy, syn-
dactyly, epilepsy, dysarthria, ichthyosis, optic atrophy, pe-
ripheral neuropathy, retinitis pigmentosa, and cataract;
and (2) by the mode of inheritance, which can be auto-
somal dominant, autosomal recessive (AR), or X-linked.6992 The American Journal of Human Genetics 82, 992–1002, April 2Patients with HSP generally share the same core clinical
features: spastic gait, lower-limb hypertonicity, pyramidal
weakness, hyperreﬂexia, and extensor-plantar responses
(Babinski signs). There is considerable variation, however,
in age at onset and in the severity of spasticity. Further-
more, in ‘‘complicated’’ HSP, the accompanying neurolog-
ical problems are highly variable both within and among
families.2,6
Concerning their molecular bases, at least 38 HSP and re-
lated genes have been localized or identiﬁed.6 Sixteen loci
are associated with ‘‘complicated’’ AR-HSPs, but only ﬁve
of the genes have been identiﬁed: SPG7 on chromosome
16p24.3, encoding paraplegin (MIM 602783);7 SPG11 on
chromosome 15q21.1, encoding spatacsin (MIM 604360);8
SPG20 on chromosome 13q12.3, encoding spartin (MIM
607111);9 SPG21 on chromosome 15q22, encoding
maspardin (MIM 608681);10 and SACS on chromosome
13q12.12, encoding sacsin (MIM 270550).11 The molecular
mechanisms leading to axonal degeneration are probably
as diverse and complex as the genetics of HSPs, but abnor-
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function have been suggested to contribute to the dysfunc-
tion or degeneration of the corticospinal tract in several of
these diseases, particularly through the analysis of SPG4
and SPG7 mouse models.6,12,13
SPG15, a ‘‘complicated’’ AR-HSP, was initially identiﬁed
in association with pigmentary maculopathy (Kjellin syn-
drome; MIM 270700)14,15 in two Irish families and map-
ped to a region of 16 Mega bases (Mb) on chromosome
14q22-q24 between the D14S1038 and D14S61 loci.16
Very recently, we reﬁned the SPG15 locus to 5.3 Mb
between markers D14S981 and rs8688, and we estimated
that it accounts for 15% of AR-HSP,17 a frequency quite
similar to that of SPG11.18 In addition, we showed that
the clinical features varied among patients and families
but cognitive impairment and distal amyotrophy were fre-
quent (Table 1). Peripheral neuropathy, maculopathy, cer-
ebellar ataxia, thin corpus callosum, and white matter ab-
normalities on MRI were also observed but were not
constant clinical features of the disease.17,19
Here, we report the reﬁnement of the SPG15 locus to
a 2.64 Mb genetic interval on chromosome 14q23.3-
q24.2 and the identiﬁcation of truncating mutations in
the zinc-ﬁnger FYVE domain containing 26 gene
(ZFYVE26), also known as KIAA0321, that segregate with
‘‘complicated’’ AR-HSP, with or without maculopathy, in
eight families.
Subjects and Methods
Patients and Controls
We analyzed seven previously described SPG15-linked AR-HSP
families16,17,19 and one large kindred partially reported20 that we
found signiﬁcantly linked to SPG15 with a signiﬁcant multipoint
LOD score of þ3.3 (data not shown). Affected patients and their
relatives were recruited with their informed and written consent,
as prescribed by the law on bioethics of the European Community
and after approval by the local ethics committee (approval No. 03-
12-07 granted to A.B. and A.D. by the ‘‘Comite´ Consultatif pour la
Protection des Personnes et la Recherche Biome´dicale,’’ Paris-
Necker). Genomic DNA from 300 unrelated healthy individuals
(Europeans, n¼ 200;North Africans, n¼ 100)was used as a control
panel for molecular studies.
Linkage Analysis
To further reduce the SPG15 interval, indirect genetic studies
were undertaken in the three families reported by Elleuch
et al.17 Primers ﬂanking new polymorphic nucleotide repeats
(supplementary table) from the Working Draft of the Human Ge-
nome available at UCSC were designed. Genotyping was per-
formed via PCR with ﬂuorescently labeled primers, electrophore-
sis on an ABI-3730 sequencer, and analysis with GeneMapper
software 4.0 according to the manufacturer’s recommendations
(Applied Biosystems). Haplotypes were reconstructed manually
by minimization of the number of recombination events. Ge-
netic distances between markers were those of the Marshﬁeld
Centre for Medical Genetics, and map positions were veriﬁed
on the draft of the Human Genome sequencing (UCSC and
Ensembl centers).The AMutation Screening
Four genes were screened for mutations in one affected member
of each family, with the use of primers ﬂanking the exon and in-
tron-exon boundaries: ZFYVE26 (for zinc-ﬁnger FYVE domain
containing 26, GenBank accession number NM_015346; 42
exons; see Table S1, available online, for the primers); PLEK2 (en-
coding pleckstrin 2, NM_016445; 9 exons); PLEKHH (for pleckstrin
homology domain containing, family H [with MyTH4 domain]
member 1, NM_020715; 9 exons); and WDR22 (encoding WD
repeat domain protein 22, NM_003861; 9 exons). PCR products
were sequenced with the use of the Big Dye Terminator Cycle
SequencingKit v3.1 (Applied Biosystems) on anABI-3730 automated
sequencer. Nucleotides were numbered relative to the A of the start
codon (ATG) of the ZFYVE26 cDNA sequence (NM_015346).
Quantiﬁcation of ZFYVE26 mRNA in Human Tissues
by RT-PCR
ZFYVE26 mRNA expression was analyzed semiquantitatively via
RT-PCR in adult human tissues, normalized with respect to vimen-
tin (VIM) expression. One microgram of commercially available
RNA (Human Total RNA Master panel II, Clontech) was reverse-
transcribed with the High Capacity cDNA Archive Kit (Applied
Biosystems) primed with Oligo d(T)16 (Applied Biosystems) in
accordance with the supplier’s recommendations. A 470 bp frag-
ment from exon 2 to exon 5 was ampliﬁed with forward primer
50-AGGGGATATCCCAAAGAGGG-30 and reverse primer 50-CCT
TTCGAATGAGGTCCACC-30, and a 507 bp fragment including
exons 38 to 42 was ampliﬁed with forward primer 50-TCACC
ACTTTGCCTCTGCCA-30 and reverse primer 50-GCCACTGGGCA
CAGATGTCT-30. A 274 bp fragment of VIM (GenBank accession
number NM_003380) containing exons 1 to 4 was ampliﬁed
with forward primer 50-ACCAGCTAACCAACGACAAA-30 and
reverse primer 50-TGCTGTTCCTGAATCTGAGC-30, as a reference.
Expression of Rat ZFYVE26mRNA Detected by in situ
Hybridization
Adult (P68, 200 g) Sprague-Dawley rats (Charles River) were killed
by decapitation, and their brains were rapidly extracted and frozen
in isopentane at50C. Sections were cut every 600 mm on a cryo-
stat (20C) from the medulla to the striatum (þ1.7 mm from the
bregma, according to the rat brain coordinates of Paxinos and
Watson), thaw-mounted on glass slides, and stored at 80C.
Whole rat embryos (E14.5) were ﬁxed in PFA 4% for 24 hr, rinsed
in PBS, dehydrated in graded ethanols (70% to 100%), rehydrated
with the reverse procedure, cryoprotected in 15% sucrose for
24 hr, then frozen in isopentane at 35C. Sixteen micron slices
were cut every 250 mm and stored.
Rat ZFYVE26mRNA expression was probed with three 34 bp an-
tisense oligonucleotides recognizing exon 15 or the 50 or 30 por-
tions of the large exon 21, designed with Helios ETC oligo design
software (Helios Biosciences, Paris, France) from the mRNA se-
quence (XM_234335.3) of Rattus norvegicus. Each oligonucleotide
or a mix of the three oligonucleotides gave identical results. A
mix of three sense oligonucleotides was used as negative control.
In brief, the oligonucleotides were labeled with [35S]-dATP with
terminal transferase (Amersham Biosciences) to a speciﬁc activity
of 5 3 108 dpm/mg. The day of the experiment, slices were ﬁxed
in 4% formaldehyde in PBS, washed with PBS, rinsed with water,
dehydrated in 70% ethanol, and air-dried. Sections were then cov-
ered with 140 ml of hybridization medium (Helios Biosciences,
Paris, France) containing 3–5 3 105 dpm of the labeledmerican Journal of Human Genetics 82, 992–1002, April 2008 993
Other
Signs ENMG
Brain
MRI
Pes cavus,
pseudo bulbar
dysarthria,
severe UL and LL
amyotrophy
Axonal
PNP
Normal
Pes cavus,
scoliosis, pseudo
bulbar dysarthria,
moderate LL
amyotrophy
Axonal
PNP
Normal
Severe LL
amyotrophy
ND ND
None ND Normal
ity
Pseudo bulbar
dysarthria; oral
and hand
dystonia-
Sensorineural
hearing deficit
Axonal
PNP
TCC, WMA,
marked cortical
atrophy, mild
cerebellar
atrophy
Pseudo bulbar
dysarthria.
Sensorineural
hearing deficit
Axonal
PNP
TCC, cortical
and cerebellar
atrophy
y
y
Pseudo bulbar
dysarthria and
nystagmus
Sensorineural
hearing deficit
Axonal
PNP
TCC and WMA
Pseudo bulbar
dysarthria
Normal TCC
Pes cavus ND TCC, cortical and
mild cerebellar
atrophy
ion
Epilepsy, distal
amyotrophy,
bladder
dysfunction
Normal Diffuse cerebral
atrophy
ion
Bladder
dysfunction,
pseudo bulbar
dysarthria, distal
amyotrophy,
Normal ND
9
9
4
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
8
2
,
9
9
2
–
1
0
0
2
,
A
p
ril
2
0
0
8Table 1. Clinical and Paraclinical Features of 22 SPG15 Patients
Family/Patient
Sex/Age
at onset (yrs)
Disease
Duration (yrs)
Functional
Handicap
(Scale)
LL/UL
Reflexes
Cognition
Cerebellar
Signs
Visual
Function
Mental
Retardation
Cognitive
Deterioration
16/161 M/12 20 Severe (6/7) Brisk/Brisk þ (Moderate) No No Normal
30/274 F/11 17 Severe (6/7) Very
brisk/Brisk
þ (Moderate) No No Normal
30/275 F/8 19 Severe (5/7) Very
brisk/Brisk
þ (Moderate) No No Normal
30/279 F/8 1 Mild (2/7) Very
brisk/Normal
þ (Mild) No No Normal
761/3 M/12 26 Severe (6/7) Very
brisk/Very
brisk
No þ (Severe) þ Reduced
visual acu
761/5 F/12 22 Severe (6/7) Very
brisk/Normal
No þ (Mild) þ Normal
761/9 M/9 12 Severe(5/7) Very
brisk/Brisk
No þ (Mild-Moderate) No Pigmentar
retinopath
761/10 M/5 12 Moderate (4/7) Very
brisk/Normal
þ No No Normal
17/168 F/14 6 Moderate (3/7) Brisk/Normal No No No Normal
1007/3 F/13 20 Severe (6/7) Brisk/Brisk þ þ þ Macular
pigmentat
1007/4 M/14 18 Severe (6/7) Brisk/Brisk þ þ þ Macular
pigmentat
Normal Focal dystonia,
distal amyotrophy,
bladder
dysfonction
Normal ND
Normal Decreased
vibration sense,
distal amyotrophy,
pes cavus, bladder
dysfunction
Axonal PNP ND
Normal Decreased
vibration sense,
distal amyotrophy,
pes cavus
ND ND
Normal Decreased
vibration sense
ND ND
Normal Pes cavus, Axonal PNP ND
ND Decreased
vibration sense
ND ND
ND Decreased
vibration sense
ND ND
ND Pes cavus, ND ND
Normal Decreased
vibration sense,
distal amyotrophy,
bladder
dysfunction
ND ND
Normal Raynaud
phenomenon,
high-arched
palate, wide
interdental
spaces, distal
amyotrophy,
bladder
dysfunction
Axonal PNP TCC, WMA,
mild cortical
atrophy
Normal Hands
extrapyramidal
rigidity, mild hand
tremor, decreased
vibration sense,
distal amyotrophy,
ND TCC, WMA
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
8
2
,
9
9
2
–
1
0
0
2
,
A
p
ril
2
0
0
8
9
9
51007/5 M/16 14 Severe (6/7) Brisk/Brisk þ þ þ
353/3 F/12 20 Severe (6/7) Brisk/Brisk No þ þ
353/4 M/10 20 Severe (6/7) Brisk/Brisk No No þ
353/6 F/10 15 Moderate (4/7) Brisk/Normal No No No
353/10 M/10 6 Moderate (3/7) Brisk/Normal No No þ
444/7 F/12 15 Severe (7/7) Brisk/Brisk No þ þ
444/6 M/12 15 Severe (5/7) Brisk/Brisk No No þ
444/9 F/16 2 Moderate (3/7) Brisk/Brisk No No No
671/10 F/<10 >13 Moderate (4/7) Very brisk/Brisk No þ No
671/4 F/18 6 Moderate (4/7) Very brisk/Brisk No þ No
671/5 F/19 4 Moderate (3/7) Brisk/Brisk No þ No
LL: lower limbs; UL: upper limbs; TCC: thin corpus callosum; WMA: white matter abnormalities; PNP: peripheral neuropathy; ND: not done.
These data have been partially reported in seven families16,17,19 and in one branch of family F761.20
oligonucleotide mix. Slices were incubated overnight at 42C,
washed, and exposed to a BAS-SR Fujiﬁlm Imaging Plate for 5–10
days. The plates were scannedwith a Fujiﬁlm BioImaging Analyzer
BAS-5000 and analyzed with Multi Gauge Software (Fuji).
Immunohistochemistry in Rat Brain
Brains were processed as for in situ hybridization. Sections were
ﬁxed in 4% paraformaldehyde/PBS, preincubated in PBS contain-
ing 6% goat serum and 0.1% triton, then incubated in the same
buffer with antibodies against NeuN (Chemicon International,
1/250, mouse) or GFAP (Dako, 1/500, rabbit), followed by biotiny-
lated horse anti-mouse or rabbit IgG and ABC reagents (Vector
Laboratories, Burlingame, CA). Labeling was revealed by auto-
radiography.
Expression of Epitope-Labeled Spastizin In Cultured
Cells
The ZFYVE26 cDNA from clone DKFZp781H1112Q (RPDZ) was
PCR-ampliﬁed with Easy-A polymerase (Stratagene) and primers
50-GGCTCAAACATGGCTGCGCT-30 and 50-CTTCTTGGAGCCTG
GGCCA-30, and the PCR product was introduced in phase with
the V5 and HIS tags in the pcDNA-3.1/V5-HIS-TOPO cloning vec-
tor, as recommendedby the supplier (Invitrogen). Theconstruction
was veriﬁed via sequencing after ligation, transformation, and
plasmid extraction—with the use of standardprocedures—and cor-
rection of an initial nonsensemutation by directed-site mutagene-
sis (Quick-Change Site-Directed Mutagenesis Kit, Stratagene).
COS-7 cells, maintained in DMEM (Invitrogen) supplemented
with 10% fetal bovine serum, penicillin (100 UI/ml) and strepto-
mycin (100 mg/ml), were plated on coverslips coated with collagen
and transfected 24 hr later with 2 mg plasmid DNA per well, in
6-well plates with DMRIE-C, according to the manufacturer’s
instructions (Invitrogen). The cells were ﬁxed for 15 min in 4%
formaldehyde, 48 hr post-transfection, and immunocytochemis-
try was performed via classical procedures with the following pri-
mary antibodies: rabbit anti-giantin (1/2000, Abcam), rabbit anti-
calreticulin (1/400, Stressgen), mouse anti-EAA1 (1/1000, BD
Biosciences), rabbit anti-Cox2 (1/400, gift of A. Lombes), mouse
anti-Lamp2 (1/200, Abcam), mouse anti-V5 (1/200, Invitrogen)
and rabbit anti-V5 (1mg/ml, Sigma). Secondary antibodies were
alexa-488 anti-mouse and anti-rabbit (1/1000, Molecular Probes)
and Cy3 anti-mouse and anti-rabbit (1/1000, Sigma). Cells were
counterstained with DAPI (1 mg/ml, Sigma) and mounted with
Fluoromount-G (Southern Biotech). Images were acquired with
a Leica SP1 confocal microscope and Leica software.
Results
Reﬁnement of the SPG15 Locus
We recently reﬁned the SPG15 locus in three large Arab
families with AR-HSP and mental retardation but not
maculopathy.17 To further restrict this interval, we ana-
lyzed additional polymorphic markers found in the Hu-
man Genome sequence draft (Table S1). Obligatory recom-
bination events between loci VNTR25TG and D14S1069
(patient 444-6) and between loci D14S588 and D14S1029
(Individual 353-11, who is still unaffected at age 18 and as-
sumed to be a noncarrier of the disease gene)17 reﬁned the
centromeric and telomeric boundaries of this locus to996 The American Journal of Human Genetics 82, 992–1002, April 2a 2.64 Mb interval on chromosome 14q23.3-q24.2 (Fig-
ure S1) containing 23 known genes and ﬁve putative
new genes (Figure 1).
Candidate-Gene Analysis
Mutations causing other HSPs have been reported to affect
not only cellular processes such as intracellular trafﬁcking
and mitochondrial function but also myelination and
development of corticospinal tract.2,6,12,13 This informa-
tion provided us with criteria for selecting candidate genes
located in the 2.64 Mb SPG15 interval (Figure 1). We ﬁrst
sequenced the exon and intron-exon boundaries of PLEK2,
PLEKHH1, and WDR22. No disease-causing alterations,
only already reported single-nucleotide polymorphisms
(reported at UCSC, available on request), were found in
several affected patients of the eight families.
We then analyzed the gene encoding ZFYVE26, which
appeared to be a good candidate, given that missense
and nonsense mutations in two other genes of the same
family were recently identiﬁed in patients with SPG33
(ZFYVE27 on chromosome 10q24.2; MIM 610244)21 and
Charcot-Marie-Tooth disease 4H (FGD4 on chromosome
12p11.21; MIM 611104).22,23 Six different homozygous
truncating ZFYVE26mutations were detected in the index
patients of the eight families (Figures 1 and 2) linked to
SPG15.16,17,19 Two were nonsense mutations: c.1477C/
T in two consanguineous Tunisian families (F16 and F17)
with similar ﬂanking haplotypes, suggesting a common
ancestral event (data not shown); and c.4312C/T in
patients from two apparently unrelated consanguineous
families from Morocco (F444) and Ireland (F1007), in
which the mutation probably resulted from deamination
of cytosine 4312 located in a CpG pair, a documented
mechanism of mutation.24 Twomutations were frameshift
deletions: a 70 base-pair deletion (c.6702_6771 del) in
a large consanguineous family of Arab origin from Israel
(F671) and c.2049 delT in a Tunisian kindred (F30). One
mutation (c.5485-1G/A), homozygous in patients of the
Algerian family 353, affected the splicing acceptor site and
was shown, in silico (BDGP and Cold Spring Harbor Labora-
tory web sites), to strongly alter the splice score from þ3.1
to 7.8. Finally, one mutation was a complex indel-inver-
sion rearrangement that deleted exons 21–23 in four pa-
tients from a consanguineous Italian family (F761) and
lead to a premature stop codon (Figure 2). The sixmutations
segregated with the disease in all eight families (Figure 2)
and they were not detected in a panel of 600 chromosomes
from unrelated controls (Caucasians, n ¼ 400; North
Africans, n ¼ 200).
Phenotype of SPG15 Mutation Carriers and
Phenotype-Genotype Correlations
Some of the clinical features of the patients were reported
previously and are summarized in Table S1.16,17,19,20 The
overall phenotype associated with SPG15 mutations in
22 affected patients was early-onset spastic paraplegia
(range: 5 to 19 years) associated with additional008
Figure 1. Critical Region of the SPG15 Locus, Structure of the ZFYVE26 Gene, and Mutations Identified in Eight SPG15 Families
(A) Physical and genetic map of human chromosome 14q23.3-q24.2, with markers defining the reduced SPG15 candidate interval in bold.
Location and direction of transcription (arrow) of the known genes are schematically represented. The candidate genes analyzed in this
study and in a previous report17 [indicated with ‘‘#’’] are indicated by black boxes. Distances on chromosome 14 are indicated according to
the Ensembl and UCSC Genome Browser databases.
(B) Structure of the ZFYVE26 gene (GenBank NM_015346) and location of the six different disease-causing mutations. The gene, located
on chromosome 14q24.1, is transcribed from telomere to centromere and consists of 42 exons covering a genomic region of 70,063 bp.
The full-length transcript is 9,688 bp long, with a coding sequence (exons 2–42) of 7,620 bp (mRNA NM_015346.2). The coding region is
indicated in gray, and untranscribed regions (UTRs) (50 and 30) are indicated in white. The mutations are numbered according to the
nomenclature of the Human Genome Variation Society, such that þ1 is the A of the start codon (ATG) of the cDNA sequence.
(C) Putative functional domains (boxes) present in spastizin (according to Predictprotein).neurological symptoms that varied among patients and
families: cognitive deterioration or mental retardation
(73%, 16/22), axonal neuropathy (67%, 8/12), mild cere-
bellar signs (36%, 8/22), and, less frequently, a central
hearing deﬁcit, decreased visual acuity, or retinal degener-
ation. A thin corpus callosum and white matter hyperin-
tensities were found on brain MRI in 64% (7/11) and
36% (4/11) of the patients, respectively, independent of
disease duration.
All mutations resulted in the loss of the c-terminal puta-
tive leucine zipper domain, and they resulted in the loss of
the FYVE domain as well in all but one family (F671). The
phenotype in this family did not differ signiﬁcantly from
that of the other families. Given that all mutations resulted
in premature stop codons, the RNA is probably degraded
by nonsense-mediated mRNA decay, but this could not
be conﬁrmed because cells of SPG15 patients were not
available.The AAnalysis of the Expression of the SPG15 Gene
In order to obtain insight into the function of the SPG15
gene, we ﬁrst analyzed expression of ZFYVE26 mRNA by
RT-PCR on total RNA from various human tissues. It was
widely expressed, but most strongly in the adrenal gland,
bone marrow, adult brain, fetal brain, lung, placenta, pros-
tate, skeletal muscle, testis, thymus, and retina (Figure S2).
Intermediate levels were detected in other structures, in-
cluding the spinal cord.
When the expressionofZFYVE26was investigated by the
use of in situ hybridization in adult rat brain (P68), mRNA
levels were generally low but strong signals were observed
in the pineal gland, the edges of the lateral ventricles, the
granular layer of the cerebellum, and thehippocampus (Fig-
ure 3 andFigure S3). Interestingly, expressionwaswider and
stronger in rat embryos (E14.5) than in adult brain
(Figure S3), particularly in the spinal cord and the cortical,
cerebellar, thalamic, and hippocampal neuroepithelia.merican Journal of Human Genetics 82, 992–1002, April 2008 997
Figure 2. Pedigrees Showing Segregation of Disease-Causing Mutations in ZFYVE26 in Eight Families Linked to SPG15
Square symbols represent men, circles represent women. Affected subjects are represented with filled symbols. The numbers are an
internal reference for each sampled individual. The genotypes are indicated below the analyzed individuals. ‘‘þ’’ indicates wild-type allele.
For the detection of the genomic rearrangement in family 671, primers 21aF and 23R (Table S1) were used, and they generated a 238bp-
fragment in mutation carriers only.998 The American Journal of Human Genetics 82, 992–1002, April 2008
Figure 3. Expression Profile of ZFYVE26
Comparison of ZFYVE26 (SPG15) and KIAA1840 (SPG11) mRNA expression in the adult rat brain (P68) via in situ hybridization with a pool
of three sense or antisense probes. Both ZFYVE26 and KIAA1840 expression resembled expression of the neuronal marker NeuN more than
expression of the glial marker GFAP labeled on adjacent slices. No specific staining was observed with the sense probes. Expression
of ZFYVE26, like KIAA1840, was low throughout the brain except in the following structures: HIP, hippocampus; PG, pineal gland; GrC,
granular cell layer of the cerebellum; and the edges of the ventricles (DV3, third ventricle; LV, lateral ventricles). Similar results for both
genes were obtained on adjacent slices with use of the pool of three probes or each probe independently.The ZFYVE26 protein, which we suggest calling ‘‘spasti-
zin’’ (SPASTIcity due to the ZFYVE26 proteIN), belongs to
the FYVE-ﬁnger family, which includes the early endosome
antigen 1 (EAA1, MIM 605070), involved in endocytic
membrane trafﬁcking.25–27 Because there is yet no antibody
against endogenous spastizin, we explored its subcellular
location with overexpression of a spastizin-HIS-V5 fusion
protein in COS-7 cells. Epitope-tagged wild-type spastizin
expressed in COS-7 cells and immunolabeled with anti-
bodies against the V5 tag was partially colocalized in small
dots or vesicles with immunolabeled endosomal marker
EAA1 and calreticulin (CALR, MIM 109091), a marker of
the endoplasmic reticulum, but notwith giantin (GOLGB1,
MIM 602500), lysosomal-associated membrane protein 2
(LAMP2, MIM 309060), or mitochondrially encoded
cytochrome c oxidase II (MT-CO2 [COX2], MIM 516040),
markers of the Golgi apparatus, lysosomes, and mitochon-
dria, respectively (Figure 4).
Discussion
In this study, we reﬁned the SPG15 locus to a 2.64 Mb
interval on chromosome 14q23.3-q24.2, which allowed
us to identify ZFYVE26 as the causative gene. The sixTheidentiﬁed mutations segregated with a complex pheno-
type in eight families previously linked to SPG15 (Figure 1
and 2) and were not found in a large series of control chro-
mosomes.
This study and previous reports17,19 have demonstrated
the broad clinical variability of Kjellin syndrome, which
is complete in only a minority of our mutated patients.
The core feature common to all our mutated cases was a
severe and early-onset spastic paraplegia frequently asso-
ciated with mental retardation and/or cognitive deteri-
oration. Retinal degeneration—a major feature of this syn-
drome—as well as the MRI anomalies can be absent in
some patients, even after long disease durations.17,19
Spastizin Functions
Spastizin, the product of the ZFYVE26 gene, is one of more
than 30 different proteins with a FYVE domain in mam-
mals.25,27 The FYVE domain is a zinc-ﬁnger-binding do-
main, highly conserved from yeast to humans, character-
ized by the presence of eight conserved cysteine residues,
the third of which is ﬂanked by characteristic basic amino
acids, CX2CX9–39RRHHCRXCX4CX2–6CX4–48CX2C (X ¼
nonconserved amino acid residues), suggested to bind
the FYVE-ﬁnger proteins to endosomes.25–28 The majority
of FYVE-ﬁnger proteins are involved in interactions withAmerican Journal of Human Genetics 82, 992–1002, April 2008 999
different forms of phosphoinositides (e.g., phosphatidyli-
nositol 3-phosphate [PtdIns3P; PI3P]), which are found
mainly in endosomes and serve as regulators of endocytic
membrane trafﬁcking.27,28 These phospholipids are com-
ponents of membranes and have been implicated in the re-
cruitment of proteins to membranes for signal transduc-
tion, membrane trafﬁcking, cytoskeletal functions, and
apoptosis.25 FYVE ﬁngers bind with much higher afﬁnity
to membrane-associated PI3P than to its soluble analogs,
explaining why most FYVE-ﬁnger proteins are associated
with endosomal trafﬁcking.27,28
The colocalization of spastizin withmarkers of the endo-
plasmic reticulum and endosomes suggests that this pro-
Figure4. CellularExpressionof Spastizin
A spastizin-HIS-V5 fusion protein was
overexpressed in COS-7 cells and labeled
48 hr after transfection with an antibody
against the V5 tag (green). The Pearson co-
efficient (Rr) was calculated for estimation
of the degree of colocalization between
spastizin-HIS-V5 and the organelle markers
(in red). The values range from 1.0 (not
colocalized) to þ1.0 (fully colocalized).
Nuclei are counterstained with DAPI
(blue). Images were obtained with a Leica
SP1 confocal microscope (objective 363,
scale bar represents 10 mm). Spastizin par-
tially colocalized with the endosomal
marker EEA1 and the endoplasmic-reticu-
lum marker calreticulin but did not show
any significant colocalization with Golgi
(anti-giantin), mitochondria (anti-Cox2),
or lysosomes (anti-Lamp2).
Expression of a V5-tagged fusion protein of
the expected size was verified on Western
blots of cell extracts with a V5 antibody
(data not shown).
tein plays a role in endosomal traf-
ﬁcking, but examination of the
endogenous protein will be necessary
to conﬁrm these results, which con-
tribute to accumulating evidence
that defects in trafﬁcking are an im-
portant underlying cause of HSP.
Additionally, the temporal and re-
gional distribution of ZFYVE26
mRNA observed via in situ hybridiza-
tion inadult rat brainwasvery reminis-
cent of the expression of the SPG11
gene,8 the clinical features of which
overlap those of SPG15, suggesting
that the corresponding proteins could
interactor function inacommonpath-
way (Figure 3). In addition, the stron-
ger and wider expression of ZFYVE26
in embryos, including in spinal cord
and in cerebellar, hyppocampal, thalamic, and cortical
neuroepithelia, suggests a critical role of this gene during
the development of the nervous system (Figure S3).
Pathogenic Mechanisms
It has beenpreviouslydemonstrated that an intact FYVEdo-
mainandseveral conservedcysteine residues in thisdomain
are necessary for the endosomal localization of the proteins
of this family.26,28,29 Interestingly, all of themutations iden-
tiﬁed in our SPG15 families in ZFYVE26 were truncating
mutations located upstream of the putative leucine zipper
domain, and all except one (F671) were found upstream
of the FYVE domain. Nonsense-mediated mRNA decay,1000 The American Journal of Human Genetics 82, 992–1002, April 2008
a well-documented cellular mechanism,30,31 probably con-
tributes to the loss of function of this protein in all cases.
It is interesting to note that a missense mutation in the
FYVE-domain protein encoded by ZFYVE27 was identiﬁed
in an ‘‘uncomplicated’’ form of autosomal-dominant HSP
in a single German family with SPG33.21 The ZFYVE27
protein product was found to bind spastin (SPG4), another
HSP-associated protein, but the missense mutation in
ZFYVE27 induces an aberrant structure which interferes
with its interaction with spastin and thus with microtu-
bules.21 Whether spastizin also binds spastin remains to
be determined.
In conclusion, the identiﬁcation of ZFYVE26 as the gene
responsible for SPG15 has increased our knowledge of the
genetic and clinical heterogeneity of HSPs and will help to
orient the molecular analysis of patients in view of a diag-
nosis. Our in situ hybridization and colocalization studies
are also a starting point for our understanding of the nor-
mal cellular mechanisms in which spastizin participates
and for the elucidation of the mechanisms underlying ax-
onal degeneration in the SPG15, which probably include
endosomal trafﬁcking and development anomalies. Eluci-
dation of thesemechanisms will be necessary for the devel-
opment of effective therapeutic strategies.
Supplemental Data
Three ﬁgures and one table are available with this paper online at
http://www.ajhg.org/.
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